ArticleBJS open2025
Tolerability, toxicity, and outcomes following surgical and non-surgical approaches to the management of patients with locally advanced oesophageal squamous cell carcinoma: multicentre retrospective cohort study.
Article in BJS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundOesophageal squamous cell carcinoma is the predominant histopathological subtype of oesophageal cancer across the world, representing as many as 90% of all cases; however, within Western cohorts, it is a low-prevalence disease, and, as such, appropriately powered trials to establish a standard treatment paradigm in this population remain challenging. The aim of this study was to assess current practices and compare outcomes for patients with locally advanced oesophageal squamous cell carcinoma across the UK and Ireland.
methodsThis was a retrospective multicentre cohort study of patients managed with curative intent for squamous cell carcinoma of the middle or distal oesophagus in 23 hospitals across the UK and Ireland. Consecutive patients diagnosed between 1 January 2012 and 31 December 2016 were included.
resultsThis study included 1545 patients, of whom 923 (59.7%) received definitive chemoradiotherapy, 286 (18.5%) neoadjuvant chemotherapy + surgery, 218 (14.1%) neoadjuvant chemoradiotherapy + surgery, and 118 (7.6%) surgery alone. Neoadjuvant chemoradiotherapy + surgery was associated with significantly longer survival than neoadjuvant chemotherapy or definitive chemoradiotherapy (median 83.9 versus 27.8 versus 26.5 months). In propensity score-matched analysis of overall survival, patients receiving neoadjuvant chemoradiotherapy + surgery had significantly longer survival than those who had definitive chemoradiotherapy (median 56.8 versus 43.1 months; hazard ratio 0.39, 95% confidence interval 0.20 to 0.78; P < 0.001).
conclusionThis multicentre retrospective cohort study suggests that, despite a majority of patients being treated with definitive chemoradiotherapy, patients undergoing neoadjuvant chemoradiotherapy and surgery have improved survival compared with those receiving definitive chemoradiotherapy or neoadjuvant chemotherapy + surgery. In the absence of robust Western randomized clinical trial data, neoadjuvant chemoradiotherapy + surgery should be considered the standard for well selected patients fit for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.